{"analyses":[{"ciLowerLimit":"0.50","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.26","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.80"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.6","upperLimit":"35.0","value":"30.3"},{"groupId":"OG001","lowerLimit":"16.3","upperLimit":"27.0","value":"21.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"description":"The primary analysis will be based on the stratified log-rank statistic to compare the two treatment arms on OS. The Kaplan-Meier product-limit estimator will be used to estimate OS distributions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 60mg cabozantinib-s-malate PO QD for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I (Cabozantinib-s-malate)"},{"description":"Patients receive 50mg sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm II (Sunitinib Malate)"}],"paramType":"MEDIAN","populationDescription":"All enrolled patients","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}